Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing - Wikidata - wikimedia - TriplyDB

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing

http://www.wikidata.org/entity/Q24626941

about

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.Implementation and utilization of genetic testing in personalized medicine.Pharmacogenetics in clinical practice: how far have we come and where are we going?Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.EHR based Genetic Testing Knowledge Base (iGTKB) Development.Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.HLA-B (*) 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand.Pharmacometabolomics Informs Viromics toward Precision Medicine.Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?Development and use of active clinical decision support for preemptive pharmacogenomics.Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Integrating pharmacogenetic information and clinical decision support into the electronic health record.Personalized medicine in cardiology: the time for genotype-guided therapy is now.HLA and disease: guilt by association.Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Genomic architecture of pharmacological efficacy and adverse events.Role of dermatology in pharmacogenomics: drug-induced skin injury.Pharmacogenetic considerations in the treatment of gout.Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Clinical application of pharmacogenetics: focusing on practical issues.Allopurinol hypersensitivity: investigating the cause and minimizing the risk.Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update.Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Recent advances in understanding and managing gout Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes.Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.

P2860

Q24567778-3BA3A659-E4F3-453C-B664-369E5E3E29C2 Q26800980-20259540-0CD1-4F84-938B-0ECD013A4E85 Q28079766-D4940214-B3CD-49D7-879B-A85458527CC4 Q31058146-D7CB62FF-DAA0-461B-97A7-D147D5533CE0 Q33666857-71BF4E33-F683-4608-80D4-D47EE12C9302 Q33953373-6DA30989-5640-4AE4-BEC0-32E04A618A91 Q34147916-77A5C57C-24FE-4F4A-AD8B-BF2F1C9DCCA3 Q34343365-21281FF8-C54A-468E-A777-4211AC28F805 Q34345953-3AE596BE-8782-4F69-8B16-179C087DBA7D Q34389432-10AFF857-6679-4C27-A94F-725DD0EF01CF Q35168561-1A685F80-E184-4084-9AF5-60DC86BC9903 Q35852441-59D1796D-B24A-433C-BFDD-D532CFFA5972 Q36085404-7E6B66D2-FC53-44AE-800F-C93A65A9043E Q36166107-D839906D-01AC-44B8-9647-CFC584243210 Q36362974-2693EEC3-A7D9-4801-BC6D-84924303CFF5 Q36398661-D64783D6-3845-4AF2-87E9-A26911252D75 Q37100410-AD0576AC-8E62-49A9-860D-52B153946C4D Q37368628-8BF81BC6-2602-4819-90A6-2AD99E3CC441 Q37507172-0A819995-1E36-4D85-A403-5967B116715C Q37642949-19F816D6-3BCC-49E3-B395-0D36A2F90AA6 Q37652863-17AF4974-7F38-4E1C-9608-CBABF5D411AA Q37697237-E1243481-9FAC-489F-869F-8979CD91928A Q37715400-D8718839-3A0B-42DB-AEE5-389BBB6F51B5 Q38120086-33233759-5319-4578-9520-208801DA523B Q38134171-64AE7BCB-C54B-4C59-B451-A80318B0B12C Q38164730-753A8474-9AE9-45D5-AE71-601155D4DF49 Q38219092-EC23C90E-A733-4708-AC39-0AA648F77676 Q38292930-091D2B07-1790-4800-8AC4-928DF74B9850 Q38396234-89A82AE8-CCEF-45B6-9EA0-F15DDFBDB0B6 Q38422218-AD021539-10A6-49D9-A66A-5466AC10AE8A Q38474868-47AA225A-3505-4C59-8AA0-3B22651CA8BF Q38593942-740C7391-F533-472B-ACE5-5A4C4D703845 Q38594891-710861D1-9F3D-4113-B6F0-FBF7325EEB1C Q38611191-1854E411-2CD7-46E3-A22A-0DC5DFF043CE Q38629821-21C70B6B-9DBD-4D16-9E15-6F44BD4A849B Q38654435-448E190E-788D-4997-8912-4990B1563CB4 Q39173298-DECCF508-949E-4741-8E9B-4CEACDF0BA41 Q39207801-3BD8C0F9-87D7-428C-8D41-BAEE4444BE9B Q39496541-52874C61-C1F9-42AB-AD0A-AF7BDC515EB5 Q40915728-0676F9AE-629E-4369-B638-10B94F769E71

P2860

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing

http://www.wikidata.org/entity/Q24626941

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@ast

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@en

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@nl

type

label

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@ast

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@en

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@ast

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@en

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@nl

P1433

Q24626941-0E671A57-D671-4AB4-AE8E-A226D994D42F

P1476

Q24626941-B2868E03-EEE2-4C33-A9C4-F9DCEEBE8114

P2093

Q24626941-08EABD5F-AEB5-442A-99BC-262FF924AE25

Q24626941-135ECFB9-052C-4C5B-A46B-C1C70D211C55

Q24626941-40E47A24-94F3-46F0-805A-2568BA2234A4

Q24626941-9AD23048-290D-4BD4-9F11-04FE916F712B

Q24626941-B35E8362-9D32-4643-887A-5D03947633C6

Q24626941-C7AA6D92-8345-401D-B8E8-C44555E3D88C

Q24626941-FD263C64-0DDF-42CB-A1DB-F18A2C2F0876

P2860

Q24626941-075A56B3-2C27-4EF8-8441-EEF1F09C7469

Q24626941-10D313D2-F35B-40B1-A96C-357444432DB9

Q24626941-20139D3A-10FD-43DD-AD3B-E6D8E356F735

Q24626941-23E19C62-B3CD-4E22-A89E-69898D088379

Q24626941-2E321CBE-26BB-4B4B-BF78-AB6C768E0D08

Q24626941-321C0349-48C0-476C-A2D3-DC2D2BC505B7

Q24626941-3C51D042-8B6B-48AE-A5C2-BE6FC1713B5F

Q24626941-3F3D7490-B9B6-45CE-A056-FDC5A8F58D20

Q24626941-448EB569-13BC-4169-9AE2-B959E531D0F1

Q24626941-465FAF59-4E0E-45EA-8DF6-0E2929CA4AA4

P304

Q24626941-79A065A8-070E-4A97-8E63-ACDB2849290F

P31

Q24626941-6E251463-8971-4A24-86DA-0376D9EF1CA1

P3181

Q24626941-0467D6F0-AB32-4CA3-A942-6BFBABB4DA66

P356

Q24626941-EE295B12-EEB5-45E9-9B5F-947A61C2EBF2

P407

Q24626941-9360A154-7ED1-4B98-BB54-8246D2152FBE

P433

Q24626941-733228F0-326F-4E70-ABE3-343B6A471F39

P478

Q24626941-0DA5DCCD-DF0F-474F-B650-09B46E1303FD

P577

Q24626941-A799108C-615B-40CA-A0B0-1D1D49B2DCCE

P698

Q24626941-0168F266-B5F8-45D7-BB89-380089261E2A

P932

Q24626941-2083CB7F-D0B6-4DF9-81E7-F067F98EE83A

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing

@en

P2093

C F Thorn

http://www.w3.org/2001/XMLSchema#string

J T Callaghan

http://www.w3.org/2001/XMLSchema#string

M S Hershfield

http://www.w3.org/2001/XMLSchema#string

M T M Lee

http://www.w3.org/2001/XMLSchema#string

T E Klein

http://www.w3.org/2001/XMLSchema#string

T Mushiroda

http://www.w3.org/2001/XMLSchema#string

W Tassaneeyakul

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

Dual, HLA-B27 Subtype-dependent Conformation of a Self-peptide

Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

Human leukocyte antigens and drug hypersensitivity

Medical genetics: a marker for Stevens-Johnson syndrome

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Population biology of antigen presentation by MHC class I molecules

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe

Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population

P304

153-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1867359

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CLPT.2012.209

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23232549

http://www.w3.org/2001/XMLSchema#string

P932

3564416

http://www.w3.org/2001/XMLSchema#string